文献速递肝胆胰外科

术前Oddi括约肌注射肉毒毒素不能预防远端胰腺切除术后胰瘘:PREBOTPilot随机对照试验

Preoperative Injection of Botulinum Toxin Into the Sphincter of Oddi Does Not Prevent Pancreatic Fistula After Distal Pancreatectomy: The Randomized Controlled PREBOTPilot Trial.
PubMed 文献 · Ann Surg · 2026-10-15

这项单中心、随机对照、开放标签、II期试验纳入50例择期远端胰腺切除术患者,干预组术前3-10天内镜下向Oddi括约肌注射肉毒毒素100单位,对照组无术前干预。主要终点为临床相关术后胰瘘(B/C级)和/或30天内任何原因死亡。结果显示干预组B/C级胰瘘发生率为28.6%,对照组为15%(P=0.294),试验因无效提前终止,结论不支持该干预用于预防远端胰腺切除术后胰瘘。

要点

  • 术前Oddi括约肌注射肉毒毒素未降低远端胰腺切除术后临床相关胰瘘发生率。
  • 干预组B/C级胰瘘28.6% vs 对照组15%,差异无统计学意义(P=0.294)。
  • 试验因无效提前终止,干预虽安全可行但不支持用于预防胰瘘。

核心结论

  • 术前Oddi括约肌注射肉毒毒素不能减少远端胰腺切除术后临床相关胰瘘或30天死亡率,试验因无效提前终止。

研究设计与样本

  • 干预组术前3-10天接受内镜下Oddi括约肌注射肉毒毒素100单位,对照组无术前干预。

主要发现

  • 干预组26例均成功完成Oddi括约肌注射,中位注射至手术时间6天(IQR 5-8)。
  • 41例(82%)实际行远端胰腺切除术,未观察到干预后胰腺炎。
  • 30天内B/C级胰瘘干预组6例(28.6%),对照组3例(15%),P=0.294。
  • 干预组1例死于胰瘘所致胰腺切除术后出血。

临床怎么用

  • 不推荐术前Oddi括约肌注射肉毒毒素用于预防远端胰腺切除术后胰瘘。

局限性

  • 单中心、开放标签、样本量小(50例),试验因无效提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether preoperative injection of botulinum toxin (BTX) into the sphincter of Oddi (SO) is a safe and feasible strategy to prevent postoperative pancreatic fistula (POPF) after distal pancreatectomy (DP). SUMMARY BACKGROUND DATA: POPF remains a common and potentially serious complication following DP, affecting up to 30% of patients. Pharmacologically induced sphincter relaxation by endoscopic injection of BTX into the SO has been described as a new approach to prevent POPF after DP by improved drainage of pancreatic fluid towards the duodenum. METHODS: Patients scheduled for elective primary distal pancreatectomy (DP), irrespective of the underlying disease, were included in this monocenter, randomized controlled, open-label, phase-II trial with 2 parallel arms. Patients randomly assigned to the intervention group received an endoscopic injection of BTX (100 units) into the SO 3-10 days before surgery. Patients in the control group did not undergo any preoperative intervention. The combined primary endpoint was defined as the occurrence of clinically relevant postoperative pancreatic fistula (POPF grades B/C) and/or death due to any cause within 30 days following DP. RESULTS: From March 2020 to August 2023, 50 patients were included in the trial. Subsequent to the analysis of the primary endpoint, which revealed no tendency of a beneficial effect on the rate of POPF after DP following BTX injection, even with the most favorable outcome upon further inclusion of the remaining 10 patients planned for recruitment, the recruitment was prematurely terminated. All 26 patients in the intervention group underwent successful SO BTX injection within a median of 6 (IQR of 5-8) days before surgery. DP was performed in 41 patients (82%). Postinterventional pancreatitis was not detected. Within 30 days, POPF grade B/C occurred in 6 patients in the intervention and 3 patients in the control group (28.6% vs. 15%, P=0.294). One patient in the intervention group died during the trial due to POPF-induced postpancreatectomy hemorrhage (PPH). CONCLUSION: Preoperative injection of BTX into the SO did not reduce clinically relevant POPF or 30-day mortality following DP, and the trial was prematurely terminated for futility. Although the intervention was safe and feasible, these findings do not support its use for the prevention of POPF after DP.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Mack CE, Klotz R, Klaiber U, et al. Preoperative Injection of Botulinum Toxin Into the Sphincter of Oddi Does Not Prevent Pancreatic Fistula After Distal Pancreatectomy: The Randomized Controlled PREBOTPilot Trial. Ann Surg. 2026. PMID: 42875865. doi:10.1097/SLA.0000000000007239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。